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Summary Background. Migration of epidermal Langerhans cells (LCs) in response to the
cytokines interleukin (IL)-1b and tumour necrosis factor (TNF)-a is impaired in
uninvolved skin of patients with early-onset psoriasis.
Aim. To investigate whether this impairment is a reﬂection of a systemic defect in
dendritic cells (DCs), using an established model of monocyte-derived LC-like cells
(mLCs).
Methods. CD14+ monocytes isolated from both patients with psoriasis and healthy
control volunteers were cultured in a cytokine cocktail for 5 days to promote their
differentiation into mLCs, then stimulated for 24 h with TNF-a, IL-1b (both
100 ng ⁄mL) or medium alone. Cellular surface protein expression was quantiﬁed by
ﬂow cytometry, and the ability of cells to migrate to media supplemented with C-C
motif ligand (CCL)19 was assessed using a Transwell migration assay. The cytokine
and chemokine content of supernatants was analysed by cytokine array.
Results. CD14+ cells acquired an LC-like phenotype with high expression of CD1a
and major histocompatibility complex (MHC) class II. There were no differences in the
expression of activation markers or in the secretion of cytokines by mLCs isolated from
patients with psoriasis and those isolated from healthy controls. Moreover, mLCs
isolated from both groups displayed comparable ability to migrate in vitro.
Conclusions. These data suggest that the failure of LCs to migrate in response to
stimulation in patients with psoriasis is not attributable to a systemic defect in DC
function, but is rather a reﬂection of local changes in the epidermal microenvironment.
Introduction
Psoriasis is a chronic, inﬂammatory skin disorder that
affects approximately 2% of the population. It is
considered to be an immune-mediated disease, and
consistent with this is the observation that immuno-
suppressants modulating T-cell function serve as
effective therapies for psoriasis.
1–4 More recently, atten-
tion has focused on the role of dendritic cell (DC)
subtypes in the pathogenesis of psoriasis. Some DC
subtypes, such as plasmacytoid DCs, are found only in
plaques,
5–7 whereas other subsets are also present in the
skin of healthy individuals, but are at an increased
number in plaques, such as CD11c+ cells that express
both inducible nitric oxide synthase and tumour necro-
sis factor (TNF)-a.
8
Abnormalities in the function of DCs are not merely
conﬁned solely to plaques of psoriasis. We reported
previously that the function of Langerhans cells (LCs)
within uninvolved, clinically normal skin of patients
with early-onset (presenting before the age of 40 years)
psoriasis differs markedly from the LCs of healthy
individuals. LCs are a population of skin-resident DCs
Correspondence: Dr Frances L. Shaw, The University of Manchester,




set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms.
Conﬂict of interest: none declared.
Accepted for publication 31 May 2011
Experimental dermatology • Original article CED
Clinical and Experimental Dermatology
  The Author(s)
40 CED   2011 British Association of Dermatologists • Clinical and Experimental Dermatology, 37, 40–47that reside in the epidermis. One of their functions is to
capture and process external antigens encountered at
the skin surface, and respond to such challenges (in the
presence of additional signals) by migrating via afferent
lymphatics to the skin-draining lymph nodes, where
they present antigen to T cells. The mobilization of
LCs is induced primarily by the proinﬂammatory cyto-
kines TNF-a and interleukin (IL)-1b. It is believed that
following stimulation, LCs produce IL-1b, and that this,
in addition to providing one signal for migration, also
induces adjacent keratinocytes to produce TNF-a, which
provides a second independent signal for migration.
9
Exposure via intradermal injection to either of these
cytokines, or topical exposure to contact allergens,
induces LC migration from the epidermis in healthy
individuals. However, in the uninvolved skin of patients
with early-onset psoriasis, the ability of LCs to migrate
in response to topical exposure to the contact allergen
diphenylcyclopropenone, and to the cytokines TNF-a
and IL-1b, is absent.
10
It has been shown in mice that under steady-state
conditions, epidermal LCs are repopulated by resident
proliferatingprecursors,
11aprocessthathasrecentlybeen
suggested to be dependent on transforming growth factor
(TGF)-b.
12However,underinﬂammatoryconditions,such
as UV exposure, bone marrow-derived DCs have been
demonstrated to act as precursor cells.
11 Little is known
about the repopulation of LCs in human skin, but
Geissmann et al. ﬁrst reported in 1988 that peripheral
blood CD14+ monocytes differentiate into LC-like cells
(monocyte-derived LC-like cells; mLCs) following short-
term culture in the presence of TGF-b, IL-4 and granulo-
cyte–macrophage colony-stimulating factor (GM-CSF).
13
Migratory CD14+ DCs are also able to differentiate into
mLCs in the presence of TGF-b.
14 Ginhoux et al.
expanded upon this work, demonstrating that LCs arise
from monocytes in vivo, and that monocytes with
high expression of granulocyte differentiation antigen 1
(Gr-1
hi monocytes) are the immediate circulating precur-
sors of LCs.
15 It islegitimate therefore to consider whether
the abnormal function of LCs in the uninvolved skin of
patients with early-onset psoriasis is associated with
systemic changes reﬂected by the behaviour of mLCs.
In the present study, we compared and contrasted the
phenotype and function of mLCs from healthy subjects
and from patients with early-onset psoriasis.
Methods
The study was approved by Salford and Trafford
Research Ethics Committee (08 ⁄H1004 ⁄61), and writ-
ten informed consent was obtained from all participants.
Subjects
This was a laboratory investigation comparing a patient
group with a control group matched for age and gender.
Patients of either gender aged 18–55 years of age
with no current febrile illness were enrolled in the study.
Exclusion criteria were: presence of atopy or allergy,
and use of regular systemic medication within the
4 weeks prior to study enrolment.
Patients on topical therapies were not excluded;
however, our patients presented with mild to moderate
psoriasis, and the application of active topicals apart
from emollients, if used at all, was minimal.
In total, 12 patients with early-onset psoriasis (8
women, 4 men; mean ± SD age 37.9 ± 2.8, range 21–
52) and 12 healthy controls (7 women, 5 men; age
36.2 ± 2.8; range 19–46) were enrolled in the study.
The clinical severity of patients with early-onset
psoriasis was measured using the Psoriasis Area
and Severity Index (PASI
16), and ranged from 1.3 to
29.1.
Blood samples (120 mL) were taken from each
participant, drawn into 10-mL vacuum test-tubes
coated with 171 IU lithium ⁄heparin (Southern Syringe,
Manchester, UK), and used for cell isolation.
Monocyte isolation
CD14+ cells were isolated from whole blood using a
magnetic-activated cell sorting (MACS) negative selec-
tion system according to the manufacturer’s instruc-
tions (Miltenyi Biotec, Bisley, UK).
Dendritic cell culture
CD14+ cells were cultured in ﬂat-bottomed 24-well
plates at a density of 1 · 10
6 cells ⁄mL for 5 days
in RPMI 1640 culture medium containing 10%
heat-inactivated fetal calf serum (FCS), 100 U ⁄mL
streptomycin, 100 lg ⁄mL penicillin and 292 lg ⁄mL
L-glutamine (complete RPMI; Invitrogen, Paisley, Ren-
frewshire, UK). The medium was supplemented with
10 ng ⁄mL TGF-b, 250 ng ⁄mL GM-CSF and 10 ng ⁄mL
IL-4 (R&D Systems, Abingdon, Oxfordshire, UK). Cells
were fed on day 3. On day 5, cells were resuspended in
complete RPMI supplemented with 250 ng ⁄mL GM-CSF
and 100 ng ⁄mL IL-4 at a density of 1 · 10
6 cells ⁄mL,
and stimulated with medium alone (vehicle control),
TNF-a or IL-1b (both 100 ng ⁄mL; R&D Systems,
Abingdon, UK) for 24 h. The cells were not cultured
with TGF-b at this stage so as to enable LC maturation
in response to the inﬂammatory mediators.
17 Following
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pipetting, and centifuged at 200 g for 5 min. The
supernatants were aspirated and stored at )80  C for
measurement of cytokines and chemokines. The result-
ing cells were resuspended either in 5% FCS in phos-
phate-buffered saline for ﬂow cytometric analysis, or in
complete RPMI at 2 · 10
6 cells ⁄mL for use in the
migration assay.
Flow cytometry
Cells were analysed for expression of CD14, CD54,
CD86, major histocompatibility complex (MHC) class II
and CD1a via indirect staining (FACSCalibur; Becton
Dickinson, Oxford, Oxfordshire, UK). Dead cells were
excluded by staining with 5 lg ⁄mL propidium iodide
(Sigma-Aldrich, Poole, Dorset UK) immediately before
analysis. Data were analysed using FlowJo software
(Tree Star Inc., Ashland, MA, USA).
Luminex analyses
Concentrations of cytokines and chemokines [IL-10,
interferon-c-induced protein (IP)-10, macrophage
inﬂammatory protein (MIP)-1a and TNF-a] within
culture supernatants were measured by cytokine
array (BioPlex, Bio-Rad, Hemel Hempstead, Hertford-
shire, UK) according to the manufacturer’s instruc-
tions. Analysis was performed on a multiple analyte
proﬁler (Luminex 100; MiraiBio Hitachi Genetic Sys-
tems, Alameda, CA, USA) with BioPlex software (Bio-
Rad Laboratories, Hercules, CA, USA). The limits of
accurate detection (read from the nonlinear portion of
the standard curves) for each of the cytokines (in
pg ⁄mL) were as follows: 6.4–102.2 (IL-10), 34.7–
555.9 (IP-10), 5.1–20.5 (MIP-1a) and 25.3–404.8
(TNF-a), with the lower values representing the lower
limits of detection.
Migration assay
Cells (2 · 10
5; both unstimulated and cytokine-stimu-
lated) were seeded into the upper wells of a 5-lm pore
(Transwell; Fisher, Scientiﬁc UK, Loughborough, UK)
ﬁlter. Either C-C motif ligand (CCL)19 (200 ng ⁄mL) or
bovine serum albumin (BSA, used as vehicle control),
were added to 600 lL of RPMI medium in the lower
well. Cultures were established in duplicate, and were
incubated in a humidiﬁed atmosphere of 5% CO2 in air
for 3 h at 37  C. The number of migrated cells was
counted using an automated cell counter (Casy Counter,
Roche Applied Science, Burgess Hill, West Sussex, UK).
Statistical analyses
Data were tested for normality and transformed via
ranking, if required, using GraphPad Prism software
(version 4.03; San Diego, USA). Released cytokine and
chemokine data and surface marker expression data
were analysed using two-way ANOVA followed by
Bonferroni tests as post hoc tests. P < 0.05 was consid-
ered signiﬁcant. All data are expressed either as
individuals or as the mean value ± SEM, and are for
3–8 replicates as stated.
Results
Dendritic cell phenotype
Following culture with GM-CSF, IL-4 and TGF-b,
CD14+ monocytes derived from both healthy controls
and patients with psoriasis acquired a DC-like pheno-
type, with CD14 expression decreasing to negligible
levels in both groups. Concurrently, the percentage of
CD1a+ cells at day 6 were 89.3 ± 3.8 and 88.9 ±
2.6%, in controls and patients, respectively, demon-
strating that there was no impairment in the ability of
monocytes obtained from patients with early-onset
psoriasis to differentiate into DC-like cells (Fig. 1).
Dendritic cell maturation following cytokine stimulation
Baseline expression of surface markers as measured by
ﬂow cytometry was equivalent between mLCs derived
from patients with psoriasis and from healthy controls
(Figs 1,2). mLCs derived from patients with psoriasis
were also able to respond to stimulation to the same
extent as those derived from healthy volunteers,
demonstrating that there was no impairment in their
maturation ability (Figs 1, 2). For example, stimula-
tion with IL-1b upregulated CD86 expression by
approximately threefold in both the mLCs derived
from patients and those derived from controls. CD54
expression was upregulated by both TNF-a and IL-1b
to the same extent (approximately twofold) in both
groups (P < 0.05; Fig. 2). Expression of MHC class II
in both unstimulated and stimulated cells was equiv-
alent between groups, and although there was a
slight increase in this expression following stimula-
tion, this was only signiﬁcant for the patients
following IL-1b stimulation (Fig. 2). There was a
trend for CD1a intensity to be decreased in the mLCs
derived from patients compared with those derived
from healthy controls, but this was not signiﬁcant
(P > 0.05; Fig. 2).
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These preliminary results demonstrate that there were
no differences in baseline concentrations of any of the
cytokines and chemokines analysed in the supernatants
of mLCs derived from patients with psoriasis compared
with those from healthy controls (Fig. 3). Stimulation
with IL-1b increased release of all of the cytokines and
chemokines analysed (IL-10, IP-10, MIP-1a and TNF-a)
to similar extents in both groups (P < 0.05), with the
exception of IL-10 in the mLCs derived from healthy
controls, although this lack of statistical signiﬁcance
was thought to be due to the low number of replicates in
this group rather than to a real physiological effect. In
addition, stimulation with TNF-a increased MIP-1a to
the same extent in both groups (P < 0.05). Thus, there
were no differences in concentrations of any of the
analytes following stimulation between mLCs derived
from both patients with psoriasis and healthy controls
(P > 0.05).
Transwell migration
Stimulation with both TNF-a and IL-1b induced migra-
tion to CCL19 in both healthy individuals and patients
with psoriasis (P < 0.05; Fig. 4), with the effect being
more pronounced in IL-1b-stimulated samples. The
baseline migration of mLCs to the vehicle control was
lower in the mLCs derived from the patients compared
with the healthy controls, in both unstimulated and
stimulated (TNF-a and IL-1b) cells (P < 0.05). The fold
increases in migration to CCL19 compared with BSA
were equivalent between the mLCs derived from
patients compared with those obtained from healthy
controls, following either TNF-a or IL-1b stimulation
(P > 0.05). The level of migration in response to CCL19
of TNF-a-stimulated cells was decreased in cells derived
from patients compared with those derived from healthy
controls (13.5 ± 0.9% and 19.6 ± 2.0 in mLCs derived
from patients and controls, respectively; P < 0.05).
However, this same effect was not observed in the cells
stimulated with IL-1b, in which levels of migration were
equivalent between the two groups (27.9 ± 2.4% and
30.4 ± 3.2 in mLCs derived from patients and controls,
respectively; P > 0.05).
Discussion
It is known that in the uninvolved skin of patients with
early-onset psoriasis, there is a complete inhibition of LC
migration in response to relevant cytokine stimula-
tion.
10 We therefore wanted to investigate whether this
impairment of LC function in the skin is paralleled by
changes in the phenotype and function of other DC
members. To address this, we examined the character-
istics of LC-like cells derived from peripheral blood
(a) (b)
Figure 1 Representative histograms demonstrating mean ﬂuores-
cence intensity of CD1a, CD86, CD54 and major histocompatibility
complex class II by monocyte-derived Langerhans cells derived
from both (a) healthy controls and (b) patients with early-onset
psoriasis. Each histogram displays data for unstimulated (solid line)
and cytokine-stimulated (dashed line, tumour necrosis factor-a;
dotted line, interleukin-1b; both 100 ng ⁄ mL) cells, in addition to
an isotype control (shaded histogram). MHC, major histocompat-
ibility complex.
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riasis, and compared them with mLCs derived from
healthy controls matched for age and gender. The results
demonstrated that there were no clear phenotypic or
functional differences in mLCs derived from patients with
early-onset psoriasis compared with healthy controls.
This suggests that the impairment in LC function
observed in vivo is not indicative of a generalized defect
in DC biology, but rather is either cell-type speciﬁc or due
to abnormalities in the skin microenvironment.





21 have been associated with changes in the
phenotypic and functional characteristics of monocyte-
derived DCs (i.e. CD14+ monocytes cultured in the
presence of GM-CSF and IL-4 alone). Considering the
systemic nature of psoriasis, it is reasonable to question
the involvement of circulating DCs in the pathogenesis of
thisskindisease.Inadditiontonodifferencesbeingfound
in mLCs, we also did not observe any obvious systemic
inﬂammation, in that there were equivalent numbers of
both PBMCs and monocytes in the blood drawn from
both groups. However, it is possible that any potential
increases in monocyte numbers in the patients with
(a) (b)
Figure 2 CD1a, CD86, CD54 and major
histocompatibility complex class II
expression by unstimulated (med) and
cytokine-stimulated [interleukin (IL)-1b
and tumour necrosis factor (TNF)-a; both
100 ng ⁄ mL] monocyte-derived Langer-
hans cells derived from both (a) healthy
controls and (b) patients with early-onset
psoriasis. Each individual is represented by
a single point on the graph, with the mean
displayed as a horizontal bar. *P < 0.05.
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migration to inﬂamed skin.
22
There was a tendency for a decrease in CD1a
expression in the mLCs derived from the patients
compared with healthy controls, although this was
not signiﬁcant. A reduction in CD1a expression is
indicative of DC maturation, and DCs isolated from
plaques of psoriasis have previously been demonstrated
to possess a mature phenotype, in terms of a loss of
CD1a.
23 CD1a is decreased in mLCs derived from
healthy controls that have been incubated with the
supernatants of cultured keratinocytes isolated from
plaques of psoriasis, compared with keratinocytes
isolated from healthy skin.
24 This indicates that an
alteration in the skin microenvironment in patients
with psoriasis is able to inﬂuence LC biology.
Interestingly, there was a general suppression in
migratory capacity in the mLCs derived from patients
with psoriasis compared with those from healthy
controls, with the exception of the IL-1b-stimulated
cells, in which migratory capacity was equivalent
between the two groups. It is unclear as to why
background migration decreased following stimulation
with TNF-a and IL-1b in both groups. One possible
explanation is that a stimulation-induced reorganiza-
tion of the cytoskeleton was sufﬁcient to inhibit this
(a) (b)
Figure 3 Quantiﬁcation of secreted cyto-
kines and chemokines from unstimulated
(med) and cytokine-stimulated [interleu-
kin (IL)-1b and tumour necrosis factor
(TNF)-a; both 100 ng ⁄ mL] monocyte-
derived Langerhans cells derived from both
healthy controls (a) and patients with
early-onset psoriasis (b). Each individual is
represented by a single point on the graph,
with the mean displayed as a horizontal
bar. *P < 0.05. IP-10, interferon
c-induced protein-10; MIP-1a,
macrophage inﬂammatory protein-1a.
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migration are of interest, and warrant further investi-
gation. The unstimulated, immature mLCs did not
migrate to CCL19, as expected
25 because CCL19 is a
ligand for CCR7, which is only upregulated upon
activation. Although CCL19 is generally associated
with DC migration to lymph nodes, Robbiani et al.
reported that antagonism of CCL19 prevented migration
of LCs from the epidermis following exposure to FITC.
26
There was an equivalent release of cytokines and
chemokines between the two groups, demonstrating
that there is no impairment in the ability of mLCs
derived from patients with early-onset psoriasis to
respond to cytokine stimulation. Chemokines and
chemokine ligands have been suggested to play a role
in DC and T-cell positioning within the skin. Zhou et al.
found that chemokines such as CCL19, chemokine
(C-X-C motif) ligand (CXCL)12 and monocyte chemo-
tactic protein-1 are upregulated in plaques of psoriasis
compared with skin from healthy individuals, although
it is unclear from the study as to whether there was any
alteration in the uninvolved skin.
27 Quantiﬁcation of
chemokines and ligands within the uninvolved skin
would thus be of interest with respect to the retention of
LCs within uninvolved skin.
Conclusions
The results of this investigation demonstrate that there
are neither phenotypic nor functional differences in
mLCs derived from patients with early-onset psoriasis
compared with those derived from healthy controls.
Thus, the impaired epidermal LC function observed
in vivo does not appear to represent a genetic defect in
DCs, but rather suggests an aberration in the skin
microenvironment.
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What is already known about this topic?
• Epidermal LC function is impaired in the un-
involved skin of patients with early-onset psoriasis.
• Several diseases have demonstrated associations
with changes in the phenotype and function of
monocyte-derived dendritic cells.
What does this study add?
• The impaired LC function observed in patients
with psoriasis is not reﬂective of a systemic
defect in monocyte-derived DCs and precursors of
LCs.
• The implication is that in the absence of a
systemic functional impairment of DCs, the defect
observed in LC mobilization in psoriasis is specif-
ically associated with the LC ⁄epidermal axis.
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